Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Új-Zéland2. fázis

A Study of Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell Lymphoma

A legfontosabb adatok

Ki végzi
Malaghan Institute of Medical Research
Hol
Auckland, Christchurch és Newtown (Új-Zéland)Mind a 3 helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
2. fázis
Résztvevők
60 fő, tervezett
Kezdés
2024. júl. 12.
Várható befejezés
2029. jún. 30.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Fludarabine
  • Cyclophosphamide
  • WZTL-002 CAR T-cells
A regiszteradat frissítve
2026. augusztus 7.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

A vizsgálat olyan felnőtteket keres, akiknek a nagy B-sejtes limfómája a szokásos első kemoterápia után visszatért vagy nem reagált a kezelésre. Minden résztvevő CAR T-sejtes kezelést (atlacabtagene autoleucel) kap.

Életkor
18–75 év
Nem
Mindkét nem részt vehet.
A betegség stádiuma
Szövettanilag igazolt nagy B-sejtes limfóma (több felsorolt altípus, köztük follikuláris vagy marginális zóna limfómából átalakult is), amely visszatért vagy nem reagált a kezelésre. A PET-vizsgálatnak betegséget kell mutatnia.
Korábbi kezelés
Legalább 2 ciklus első vonalbeli kemoterápia kell antraciklinnel és anti-CD20 antitesttel, majd a rekordban leírt relapszus vagy válaszhiány. Nem vehet részt, aki már kapott 3 vagy több kezelési vonalat, korábban CAR T-sejtes vagy génterápiát, illetve CD19-et célzó kezelést.

A részvétel fő kizáró okai

  • A limfóma aktívan érinti az agyat vagy az agy-gerincvelői folyadékot, vagy aktív agyi betegség van, például epilepszia, szélütés vagy demencia
  • Korábbi szilárdszerv-átültetés vagy korábbi donor őssejt-átültetés
  • Jelenlegi vagy korábbi HIV-fertőzés
  • Terhes vagy szoptató nők
  • Immunszuppresszív kezelést igénylő aktív autoimmun betegség, vagy nem kontrollált fertőzés

A regiszter feltételei, szó szerint

Mind a 38 feltétel megnézéseKevesebb

Ki vehet részt

  • Age 18 to 75 years (inclusive) at the time of informed consent
  • Signed written informed consent for this trial
  • Biopsy-proven relapsed or treatment-refractory B-cell non-Hodgkin lymphoma of the following subtypes, as per the 2022 WHO classification of haematolymphoid tumours; Large B-cell lymphomas of the following histological subtypes:; Diffuse LBCL, not otherwise specified; Diffuse large B-cell lymphoma/high grade B-cell lymphoma with MYC and BCL2 rearrangements; Large B-cell lymphoma with IRF4 rearrangement; High grade B-cell lymphoma with 11q aberrations; High grade B-cell lymphoma, not otherwise specified; Primary mediastinal large B-cell lymphoma; Follicular large B-cell lymphoma; EBV-positive diffuse large B-cell lymphoma, not otherwise specified; Diffuse large B-cell lymphoma associated with chronic inflammation; Primary cutaneous DLBCL, leg type; Large B-cell lymphoma of one of the above subtypes that has transformed from follicular or marginal zone lymphoma
  • Received adequate first-line lymphoma therapy for the qualifying histology (as defined in inclusion criterion 3 above), comprising at least 2 cycles of a standard combination regimen incorporating an anthracycline and an anti-CD20 monoclonal antibody
  • Relapsed or refractory disease meeting one of the following criteria:; Relapsed or refractory within 12 months of first-line chemoimmunotherapy, defined as:; Progressive disease following ≥ 2 cycles of chemoimmunotherapy, or; Stable disease following ≥ 4 cycles of chemoimmunotherapy, or; Partial response following ≥ 6 cycles of chemoimmunotherapy, or; Complete response followed by biopsy-proven relapse within 12 months of completing first-line chemoimmunotherapy; Relapsed or refractory following second-line chemoimmunotherapy, defined as:; Lack of complete response to, or relapse following, autologous stem cell transplantation as part of second-line therapy for the qualifying histology, or; Inability to proceed to autologous stem cell transplantation due to lack of response to 2 cycles of second-line chemoimmunotherapy incorporating both a platinum agent and an anti-CD20 monoclonal antibody
  • Positron emission tomography (PET) positive disease according to the Lugano 2014 criteria
  • Available tumour tissue (comprising a tissue block or at least 6 unstained slides) for central histological review
  • Lymphoma-related life expectancy at least 12 weeks, and life expectancy related to conditions other than lymphoma at least 12 months
  • ECOG performance status of 0 or 1
  • Adequate haematologic function, defined by:; Neutrophils ≥ 1.0 × 10\^9/L, and Platelets ≥ 75 × 10\^9/L, and; Lymphocytes ≥ 0.3 × 10\^9/L
  • Adequate renal function, defined by estimated creatinine clearance (eCrCl) or glomerular filtration rate (eGFR) >/= 45mL/min using the Cockroft Gault estimation, CKD-EPI equation or as assessed by direct measurement
  • Adequate hepatic function, defined by serum bilirubin < 2.5 × upper limit of normal (ULN) (unless attributable to Gilbert's syndrome) and alanine transaminase and aspartate aminotransferase < 3 × ULN
  • Adequate lung function, defined as ≤ Grade 1 dyspnoea according to NCI CTCAE v5.0, and oxygen saturation (sO2) ≥ 92% on room air
  • Adequate cardiac function, defined as left ventricular ejection fraction (LVEF) ≥ 40% as assessed by echocardiogram or multigated acquisition (MUGA), performed within 28 days of commencing screening
  • For female participants:; Agree to use a condom if undertaking sexual activity with any partner during lymphodepleting chemotherapy, and; If of reproductive potential agree to use a highly effective method of contraception from the time of enrolment until at least 12 months after administration of atlacabtagene autoleucel, or; Are not of reproductive potential defined as either,; being amenorrhoeic for at least 12 consecutive months with FSH 30 ≥ IU/L, or; previously undergone a sterilisation procedure
  • For male participants:; Agree to use a condom if undertaking sexual activity with any partner during lymphodepleting chemotherapy, and; If undertaking sexual activity with a female partner of reproductive potential agree to use a highly effective method of contraception from the time of enrolment until at least 12 months after administration of atlacabtagene autoleucel, and; Agree not to donate sperm for conception, or to provide gametes for in vitro fertilisation for at least 12 months after administration of atlacabtagene autoleucel
  • Participant agrees not to donate blood components at any time after receiving WZTL-002

Ki nem vehet részt

  • Patient has received 3 or more prior lines of therapy for LBCL, where 1 line of therapy is defined as 1 or more cycles of a combination chemoimmunotherapy with or without pre-planned consolidation therapy (radiotherapy, autologous stem cell transplant or immunotherapy)
  • Requirement for urgent lymphoma therapy due to tumour-related symptoms, or due to imminent risk of blood vessel, airway, urinary tract, gastrointestinal tract, nerve or spinal cord compression
  • Prior solid organ transplantation or prior allogeneic stem cell transplantation (allo-SCT)
  • History of active malignancy other than B-cell malignancy within 2 years prior to enrolment, with the exception of: adequately treated in situ carcinoma of the cervix; adequately treated basal cell carcinoma (BCC) or squamous cell carcinoma (SCC) of the skin; other localised malignancy surgically resected (or radically treated with another treatment modality) with curative intent
  • Prior treatment with:; gene therapy (including CAR T-cell therapy) or CD19-targeted immunotherapy, or; purine analogue (including bendamustine) or alemtuzumab within 6 months of enrolment, or; bispecific T-cell engager, radiotherapy or an investigational medicine within 4 weeks of enrolment, or; cytotoxic chemotherapy, systemic corticosteroids (at doses of ≥ 10 mg prednisone daily or equivalent), monoclonal antibody or antibody-drug conjugate (other than alemtuzumab) within 2 weeks of enrolment
  • Current or prior HIV infection
  • Serologic status reflecting active viral hepatitis B or active hepatitis C infection as follows:; Presence of hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with hepatitis B virus (HBV) DNA > 20 IU/mL. Patients with presence of HBcAb and/or HBsAg remain eligible if HBV DNA is undetectable (or is < 20 IU/mL), and provided they are receiving appropriate antiviral prophylaxis; Presence of active Hepatitis C infection as determined by Hepatitis C virus (HCV) RNA detected by PCR or nucleic acid testing (NAT). Patients with presence of HCV antibody, are eligible if HCV RNA is undetectable
  • Significant concomitant illnesses which would in the Investigators opinion make the patient an unsuitable candidate for the trial
  • Patient does not provide consent to enrol to an International Cellular Therapy Registry
  • Active central nervous system (CNS) involvement by lymphoma. In patients with a history of CNS disease or a clinical suspicion of current CNS disease, lumbar puncture and MRI brain must be performed within 30 days of enrolment to exclude current CNS involvement
  • Active CNS pathology including: epilepsy, seizure within the preceding year, aphasia, paresis, stroke, dementia, psychosis within the preceding year, severe brain injury, Parkinson disease, or cerebellar disease
  • Active autoimmune disease requiring current systemic immunosuppression
  • Inadequately-controlled systemic infection
  • Current New York Heart Association (NYHA) class 2 or higher cardiac symptoms, or myocardial infarction, unstable angina or other clinically significant cardiac disease within the past 6 months
  • Peripheral blood CD3+ T cells < 150/μL (0.15 x10\^9/L) as assessed by lymphocyte subset analysis
  • B-cell non-Hodgkin lymphoma of the following subtypes, as per the 2022 WHO classification of haematolymphoid tumours:; Richter transformation of chronic lymphocytic leukaemia; T-cell/histiocyte rich LBCL; Primary LBCL of immune-privileged sites; Fluid overload associated LBCL; Fibrin-associated LBCL; Plasmablastic lymphoma; Mediastinal grey zone lymphoma; Intravascular LBCL; ALK-positive large B-cell lymphoma; Lymphomatoid granulomatosis; Burkitt lymphoma; Primary effusion lymphoma; KSHV/HHV8-positive diffuse large B-cell lymphoma
  • Active sarcoidosis
  • Pregnant or lactating female
  • Known sensitivity to immunoglobulin or to components of the IP
  • Vaccination with a live virus within the 4 weeks of enrolment
  • Patients who have diminished capacity or any circumstance that would prohibit them from understanding and providing informed consent in accordance with ICH-GCP

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 75 év között vagy?

Helyszínek itt: Új-Zéland

  • Auckland City HospitalAuckland, Új-ZélandContact: Shailesh PatelRésztvevőt keres
  • Christchurch HospitalChristchurch, Új-ZélandContact: Haematology Research TeamRésztvevőt keres
  • Wellington HospitalNewtown, Új-ZélandContact: Clinical Trial UnitRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

The goal of this clinical trial is to learn if a new type of chimeric antigen receptor (CAR) T-cell therapy called atlacabtagene autoleucel is effective and safe for the treatment large B-cell lymphomas (LBCL) that have not responded to or have come back after standard chemotherapy. The main questions this trial aims to answer are:

A teljes eredeti leírásKevesebb

* What is the likelihood of complete response of the lymphoma after atlacabtagene autoleucel treatment? * What is the risk of altered brain function (neurotoxicity) after atlacabtagene autoleucel?

All eligible participants will receive atlacabtagene autoleucel; the researchers will compare the complete response rate and neurotoxicity rate with historical groups of patients who were treated with similar therapies.

Participants will:

* Have a procedure to gather white blood cells * Receive chemotherapy to prepare for the CAR T-cells * Receive atlacabtagene autoleucel CAR T-cells through a vein * Be monitored closely for the first 14 days for certain side effects * Have scans 28 days and 3, 6, 12 and 24 months after atlacabtagene autoleucel CAR T-cells to check if the treatment has worked

A vizsgálat csoportja

  • atlacabtagene autoleucel CAR T-cellsA vizsgált kezelés

    Administered at a dose of 0.5 to 1.0x10\^6 CAR+ cells per kg of body weight, capped at 0.5 to 1x10\^8 cells for subjects weighing 100kg or more."

    Kezelés: Fludarabine, Cyclophosphamide és WZTL-002 CAR T-cells

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase 2 Trial to Evaluate the Efficacy and Safety of WZTL-002 in Patients With Relapsed or Refractory Large B-cell Lymphoma (ENABLE-2)
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 12.
Kérdések a feltételekről
Forrás: NCT06486051: ki vehet részt
A regiszteradat frissítve
2026. augusztus 7.